What is 1E Therapeutics?
Founded in 2021, 1E Therapeutics operates at the intersection of biotechnology and advanced pharmacology. The company specializes in the development of first-in-class RNA-targeting therapeutics, utilizing a proprietary design platform that distinguishes it from traditional drug discovery models. By addressing chronic, life-threatening indications and evolving pathogens, 1E Therapeutics has established a robust pipeline covering oncology, immunology, and orphan neurological disorders. Its ability to pivot across diverse therapeutic areas—from anti-microbial resistance to age-related diseases—positions the firm as a high-growth entity within the competitive biotech landscape.
How much funding has 1E Therapeutics raised?
1E Therapeutics has raised a total of $120M across 1 funding round:
Angel/Seed
$120M
Angel/Seed (2021): $120M with participation from Marius Nacht
Key Investors in 1E Therapeutics
Marius Nacht
A prominent investor and entrepreneur known for backing high-impact technology and life science ventures.
What's next for 1E Therapeutics?
The infusion of capital will likely be directed toward scaling the company's lead compounds through preclinical and clinical validation phases. As 1E Therapeutics transitions from a research-heavy startup to a clinical-stage enterprise, the focus will shift toward optimizing its drug design platform for broader therapeutic applications. Strategic priorities include expanding the internal R&D team, securing intellectual property for its novel RNA-targeting mechanisms, and potentially exploring partnerships with larger pharmaceutical entities to expedite the commercialization of its oncology and immunology assets. The current funding context suggests a move toward long-term sustainability and market leadership in the RNA therapeutics sector.
See full 1E Therapeutics company page
